The Inpatient Blood-Pressure Paradox: Molecular Pathology of Adaptive Hypertension, Silent Target-Organ Injury and Iatrogenic Harm
Elevated blood pressure (BP) is common during non-cardiovascular hospitalisation, yet the biological meaning of transient inpatient BP elevation remains uncertain. Asymptomatic elevated inpatient BP is exceptionally common, having been reported in approximately 50%–72% of hospitalisations, while markedly elevated asymptomatic inpatient BP has been documented in approximately 10% of adults admitted for conditions other than hypertension [1]. The clinical scale of the problem therefore contrasts sharply with the relative absence of evidence defining when an inpatient BP elevation represents biological injury rather than contextual physiological stress.Current practice distinguishes hypertensive emergency, in which acute hypertension-mediated target-organ damage is demonstrable, from asymptomatic BP elevation, in which such injury is clinically absent. This binary framework may be biologically incomplete because acute stressors can substantially raise BP, conventional tests may miss early cellular injury, and rapid pharmacological BP reduction may itself disturb renal, coronary or cerebral autoregulation. This technical report proposes a molecular-pathology framework that treats inpatient hypertension as a dynamic interaction among pressure burden, physiological context, cellular injury and treatment response. The framework integrates tissue-of-origin cell-free DNA, including endothelial NOS3 methylation signatures, kidney-specific methylation markers and cardiomyocyte-associated methylation signatures, with urinary cellcycle-arrest biomarkers, conventional renal and cardiac indices, endothelial glycocalyx-shedding markers, endothelial extracellular vesicles and copeptin. Serial sampling before and after antihypertensive exposure is proposed to distinguish stress-dominant or potentially adaptive BP elevation from molecularly silent target-organ injury and treatment-associated tissue damage. Pressure-time burden, BP variability, rate of BP reduction and deviation from premorbid BP are incorporated rather than relying on isolated thresholds. The framework is intended for prospective multicentre validation and subsequent phenotype-stratified randomised trials, not immediate biomarker-directed treatment. If validated, molecular phenotyping could help shift inpatient BP management from treatment of a numerical threshold towards treatment of the biological process represented by that pressure.
Authors
- Birupaksha Biswas
Institutions
- Burdwan Medical College & Hospital (IN)
Publication Details
- Journal
- International Journal of Contemporary Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.37506/x4v3f023
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00